Alkermes plc. Excess Tax Benefit from Share-based Compensation, Financing Activities
Alkermes plc. (ALKS) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $4.23 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2019-02-15
- Alkermes plc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was -$889.00K.
- Alkermes plc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $512.00K, a 96.86% decline year-over-year.
- Alkermes plc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was -$268.00K, a 102.28% decline year-over-year.
- Alkermes plc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-03-31 was $4.87M, a 2.74% increase year-over-year.
- Alkermes plc. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $4.23M, a 85.20% decline from fiscal 2015.
- Alkermes plc. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $28.58M, a 11.71% decline from fiscal 2014.
- Alkermes plc. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $32.37M.
- Alkermes plc. excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $8.87M, a 104.54% increase from fiscal 2012.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$889.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | -$377.00K derived: sum of 2 quarters · filed 2019-02-15 | -$645.00K derived: sum of 3 quarters · filed 2019-02-15 | $4.23M 10-K · filed 2019-02-15 |
| 2016-09-30 | $512.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $244.00K derived: sum of 2 quarters · filed 2017-10-26 | $5.12M 10-Q · filed 2017-10-26 | $877.00K derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | -$268.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $4.61M 10-Q · filed 2017-07-27 | $365.00K derived: sum of 3 quarters · filed 2018-02-16 | $16.68M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $4.87M 10-Q · filed 2017-04-27 | $633.00K derived: sum of 2 quarters · filed 2018-02-16 | $16.94M derived: sum of 3 quarters · filed 2018-02-16 | $28.71M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | -$4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $12.07M derived: sum of 2 quarters · filed 2018-02-16 | $23.83M derived: sum of 3 quarters · filed 2018-02-16 | $28.58M 10-K · filed 2018-02-16 |
| 2015-09-30 | $16.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $28.07M derived: sum of 2 quarters · filed 2016-11-02 | $32.82M 10-Q · filed 2016-11-02 | $42.74M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $11.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $16.51M 10-Q · filed 2016-07-28 | $26.43M derived: sum of 3 quarters · filed 2017-02-17 | $41.89M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $4.74M 10-Q · filed 2016-04-28 | $14.67M derived: sum of 2 quarters · filed 2017-02-17 | $30.13M derived: sum of 3 quarters · filed 2017-02-17 | $29.95M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $25.38M derived: sum of 2 quarters · filed 2017-02-17 | $25.20M derived: sum of 3 quarters · filed 2017-02-17 | $32.37M 10-K · filed 2017-02-17 |
| 2014-09-30 | $15.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $15.28M derived: sum of 2 quarters · filed 2015-10-29 | $22.44M 10-Q · filed 2015-10-29 | $25.38M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | -$179.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $6.98M 10-Q · filed 2015-07-30 | $9.92M derived: sum of 3 quarters · filed 2016-02-25 | $11.16M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $7.16M 10-Q · filed 2015-04-30 | $10.10M derived: sum of 2 quarters · filed 2016-02-25 | $11.34M derived: sum of 3 quarters · filed 2016-02-25 | $18.56M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $2.94M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | $4.18M derived: sum of 2 quarters · filed 2016-02-25 | $11.39M 10-K · filed 2016-02-25 | $15.91M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-09-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $8.46M 10-Q · filed 2013-10-31 | $12.97M 10-Q · filed 2014-10-29 | $16.94M derived: sum of 4 quarters · filed 2014-04-30 |
| 2013-06-30 | $7.22M 10-Q · filed 2013-07-25 | $11.73M 10-Q · filed 2014-07-31 | $15.70M derived: sum of 3 quarters · filed 2014-04-30 | $15.98M derived: sum of 4 quarters · filed 2014-04-30 |
| 2013-03-31 | $4.51M 10-Q · filed 2014-04-30 | $8.48M derived: sum of 2 quarters · filed 2014-04-30 | $8.76M derived: sum of 3 quarters · filed 2014-04-30 | $8.87M 10-K · filed 2015-02-24 |
| 2012-12-31 | $3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $4.25M derived: sum of 2 quarters · filed 2013-10-31 | $4.35M 10-Q · filed 2013-01-31 | $5.56M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-09-30 | $282.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $387.00K 10-Q · filed 2013-10-31 | $1.59M derived: sum of 3 quarters · filed 2014-02-27 | $1.59M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $105.00K 10-Q · filed 2013-07-25 | $1.31M derived: sum of 2 quarters · filed 2014-02-27 | $1.31M derived: sum of 3 quarters · filed 2014-02-27 | |
| 2012-03-31 | $1.21M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $1.21M derived: sum of 2 quarters · filed 2014-02-27 | $4.33M 10-KT · filed 2014-02-27 | |
| 2011-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $3.13M 10-Q · filed 2013-01-31 | ||
| 2011-09-30 | $3.13M 10-Q · filed 2012-11-01 | |||
| 2010-03-31 | $246.00K 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |